Online inquiry

IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13662MR)

This product GTTS-WQ13662MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13662MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3518MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ15550MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ9364MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ15348MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ14657MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ6820MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ5950MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ11610MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW